PolyPeptide Group AG (XSWX:PPGN) Interest Expense: CHF-9.7 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:PPGN PolyPeptide Group AG XSWX:PPGN
73 GF Score
Price CHF45.70
GF Value CHF31.18
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is PolyPeptide Group AG Interest Expense?

PolyPeptide Group AG XSWX:PPGN -0.65% 73 Interest Expense is CHF-9.7 Mil as of Dec. 2025. GuruFocus rates XSWX:PPGN with a GF Score™ of 73/100 and a GF Value™ of CHF31.18 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. PolyPeptide Group AG's interest expense for the six months ended in Dec. 2025 was CHF 7.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-9.7 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. PolyPeptide Group AG's Operating Income for the six months ended in Dec. 2025 was CHF 20.9 Mil. PolyPeptide Group AG's Interest Expense for the six months ended in Dec. 2025 was CHF 7.0 Mil. PolyPeptide Group AG did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

PolyPeptide Group AG  (XSWX:PPGN) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

PolyPeptide Group AG's Interest Expense for the six months ended in Dec. 2025 was CHF7.0 Mil. Its Operating Income for the six months ended in Dec. 2025 was CHF20.9 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was CHF116.7 Mil.

PolyPeptide Group AG's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

PolyPeptide Group AG Interest Expense Historical Data

* Premium members only.

The historical data trend for PolyPeptide Group AG's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PolyPeptide Group AG Interest Expense Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -2.94 -2.06 -5.30 -8.35 -9.64

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.79 -8.29 -0.31 -16.72 6.99
XSWX:PPGN
73GF Score
PolyPeptide Group AG XSWX:PPGN
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PolyPeptide Group AG Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-9.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of CHF-9.7 Mil mean?
PolyPeptide Group AG (XSWX:PPGN) has a Interest Expense of CHF-9.7 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on PolyPeptide Group AG and its competitors.
Is PolyPeptide Group AG's Interest Expense too high?
PolyPeptide Group AG's current Interest Expense is CHF-9.7 Mil. Overall, PolyPeptide Group AG has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Interest Expense compare to ZTS and UTHR?
PolyPeptide Group AG's Interest Expense of CHF-9.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on PolyPeptide Group AG and its competitors. PolyPeptide Group AG's current Interest Expense is CHF-9.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (XSWX:PPGN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF31.18, compared to a current price of CHF45.70 — trading 46.6% above its estimated fair value. The current Interest Expense is CHF-9.7 Mil. PolyPeptide Group AG's overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For PolyPeptide Group AG (XSWX:PPGN), the current Interest Expense is CHF-9.7 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PolyPeptide Group AG (XSWX:PPGN) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of CHF45.70 is trading 46.6% above its estimated GF Value™ of CHF31.18. GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.

Key valuation signals for XSWX:PPGN:

  • Interest Expense: CHF-9.7 Mil
  • GF Value™: CHF31.18 vs. price of CHF45.70 (46.6% above fair value)
  • GF Score™: 73/100 with 9 warning signs

No single metric tells the full story. See the XSWX:PPGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
73GF Score

Get the complete analysis for XSWX:PPGN

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF45.70
Price
CHF31.18
GF Value